FluoroPharma Medical (FPMI) Stock Price, News & Analysis

Company Overview

FluoroPharma Medical, Inc. is a clinical-stage molecular imaging company focused on the discovery, development and commercialization of positron emission tomography (PET) imaging agents for assessment of cardiovascular and pulmonary disease. The company’s radiotracer candidates are designed to enhance the non‐invasive detection and characterization of vulnerable plaque, myocardial perfusion and pulmonary inflammation, addressing significant unmet needs in cardiology and respiratory medicine.

FluoroPharma’s lead product candidates include atherosclerotic plaque imaging agents and myocardial perfusion tracers labeled with fluorine-18, which offer the potential for wide distribution through commercial cyclotron networks. These proprietary PET agents are engineered to bind selectively to molecular targets associated with inflammation, cell death and ischemia. The company leverages its in-house radiochemistry expertise alongside collaborations with academic medical centers and contract manufacturing organizations to advance its pipeline through preclinical validation and early-phase clinical trials.

Headquartered in Burlington, Massachusetts, FluoroPharma operates primarily in the United States, with plans to extend its clinical development partnerships internationally. The management team comprises professionals with extensive backgrounds in nuclear medicine, drug development and regulatory affairs. FluoroPharma seeks to position its novel imaging agents as next-generation tools for cardiologists and pulmonologists, enabling more precise diagnosis, risk stratification and therapy monitoring.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

FPMI Stock Analysis - Frequently Asked Questions

How were FluoroPharma Medical's earnings last quarter?

FluoroPharma Medical Inc. (OTCMKTS:FPMI) released its quarterly earnings results on Friday, August, 14th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01.

How do I buy shares of FluoroPharma Medical?

Shares of FPMI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of FluoroPharma Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that FluoroPharma Medical investors own include Adicet Bio (ACET), Marin Software (MRIN), Aurora Cannabis (ACB), AB Corporate Bond ETF (EYEG), Designer Brands (DBI), Capricorn Energy (CNE) and Comcast (CMCSA).

Company Calendar

• Last Earnings: 8/14/2015
• Today: 9/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:FPMI
• CIK: 1402785
• Web: www.fluoropharma.com
• Phone: (973) 744-1565
• Fax: N/A
• Employees: 4
• Year Founded: 2003

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A